leadf
logo-loader
viewOpyl Ltd

Opyl bolsters board with new director having financial and commercial experience in health sector

Opyl works at the intersection of clinical trials, artificial intelligence and social media.

Opyl Ltd - Opyl appoints experienced finance executive to the board as Audit and Rick Committee chair
Opyl is a new generation company that provides leading biopharma and health organisations access to emerging AI-assisted technologies

Opyl Ltd (ASX:OPL) has strengthened its board with the appointment of experienced financial and commercial executive Mark Ziirsen as a director and chairman of the Audit and Risk Committee.

Ziirsen replaces Damon Rasheed who has stepped into an executive director role to leverage his expertise in the Artificial Intelligence space.

The new appointment is an experienced non-executive director and CFO of ASX-listed companies, having served as non-executive director and chair of Respiri Limited (ASX:RSH), an eHealth SaaS company supporting respiratory health management.

He also served as non-executive director and chair of the Audit and Risk Committee of Orcoda Ltd (ASX:ODA), an SaaS-based technology company.

His executive career includes senior finance leadership roles with major ASX-listed companies including Cochlear Limited, Aristocrat Leisure Limited, Coca-Cola Amatil Limited and Goodman Fielder Limited.

Financial and commercial experience

Chairman Julian Chick said: “We are delighted to welcome Mark to the board, as he brings a wealth of financial and commercial experience in the health sector.

“Mark’s expertise and networks will complement the Opyl leadership team, particularly as we extend our footprint.”

Ziirsen commenced his career with EY in business advisory, tax and management consulting.

Most recently, he was chief financial officer (CFO) and company secretary for Wiseway Group Ltd (ASX:WWG) where he successfully led the company through an IPO, listing on ASX.

Prior to that, he was CFO of listed global medtech company Anteris Technologies Ltd (ASX:AVR) and before that, director of finance and IT for Asia Pacific at hearing implant maker Cochlear Limited (ASX:COH).

He has a strong track record in delivering growth and operational improvement across multiple industry sectors (medtech/health, technology, consumer) and geographies, having worked extensively in Asia for more than 25 years.

His strong finance and operations credentials are complemented by extensive corporate finance, governance, risk management, strategy, M&A and investor relations skills.

Much of Ziirsen’s work has involved guiding high growth and early-stage companies.

“Great excitement and determination”

In accepting the board position, he said: “Opyl has a significant opportunity to evolve and further commercialise its technology platforms and I understand the capability and global opportunity for the company.

“It is with great excitement and determination that I join the Opyl board to assist in making a significant contribution to the ongoing growth of the business.”

With the recent priority focus on accelerating the development of the Opyl Clinical Trial Predictor Tool, Damon is taking a more active role in supporting the advancement of technologies within the company, leveraging his expertise in AI.

Quick facts: Opyl Ltd

Price: 0.19 AUD

ASX:OPL
Market: ASX
Market Cap: $7.01 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Opyl Ltd named herein, including the promotion by the Company of Opyl Ltd in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Full interview: Opyl is new name of digital health track company ShareRoot

Opyl Limited (ASX:OPL) chief executive officer Michelle Gallaher updates Proactive on the renaming of the global digital health track company formerly known as ShareRoot Ltd (ASX:SRO). This heralds the company’s entry into the rapidly expanding global digital health and artificial...

on 9/12/19

3 min read